Skip to content
AnalystLens

Insmed 8-K Report, Regulation FD Disclosure (May 30, 2024)

Reports
Regulation FD·Other Events·Exhibits & Filings
Filing Date
Filed May 30, 2024
Period End
May 29, 2024
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated (Nasdaq: INSM) filed this Form 8-K to report the terms of an underwritten public offering of its common stock.

On May 29, 2024, the company entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives of the underwriters, to sell 12,621,359 firm shares at a price of $49.1825a per share after underwriting discounts and commissions. The underwriters also held a 30-day option for 1,893,203 additional shares, which they exercised in full on May 30, 2024. The filing states that net proceeds to the company, before other estimated offering expenses, are approximately $713.9 million.

The offering is being made under the company's automatically effective Form S-3 shelf registration statement (No. 333-272088), and closing is expected on May 31, 2024, subject to customary conditions. The pricing press release furnished as Exhibit 99.2 states the public offering price was $51.50b per share and that gross proceeds are expected to be approximately $650 million. The company intends to use net proceeds to fund continued research and development of brensocatib, pre-commercial and, if approved, commercialization activities for brensocatib, further commercialization and development of ARIKAYCE, research and development of treprostinil palmitil inhalation powder (TPIP), and other research product candidates, and for general corporate purposes, including business expansion activities.

Exhibit 99.1, the May 28, 2024 press release, announced the proposed offering of $500 millionc of common stock, with a 30-day option for up to an additional 15% of shares. The filing also includes a legal opinion from Hunton Andrews Kurth LLP regarding the shares (Exhibit 5.1). The forward-looking statements in the press releases flag risks including ARIKAYCE commercialization and full approval, regulatory approvals for brensocatib and TPIP, reliance on third-party manufacturers, and the company's history of operating losses and its ability to repay existing indebtedness.

02—Key points

Key Highlights

  1. Insmed agreed to sell 12,621,359 firm shares of common stock under an Underwriting Agreement dated May 29, 2024, with Goldman Sachs & Co. LLC and Leerink Partners LLC as representatives of the underwriters.
  2. The underwriters exercised in full their 30-day option for 1,893,203 additional shares on May 30, 2024.
  3. Underwriters will purchase the shares at $49.1825 per share after underwriting discounts and commissions, with net proceeds to the company of approximately $713.9 million before other estimated offering expenses.
  4. The pricing press release sets the public offering price at $51.50 per share, with expected gross proceeds of approximately $650 million.
  5. Stated use of proceeds includes funding R&D and pre-commercial and, if approved, commercialization activities for brensocatib, activities related to ARIKAYCE, R&D for TPIP, other research product candidates, and general corporate purposes.
  6. The offering is made under an automatically effective Form S-3 shelf registration statement (No. 333-272088) filed May 19, 2023, and closing is expected on May 31, 2024.
  7. The company's only approved product is ARIKAYCE, and the press release notes risks tied to its commercialization, full FDA approval, and reliance on third-party manufacturers.

03—Questions

Frequently Asked Questions

  1. How many shares were sold in the offering, and was the option exercised?

    Insmed agreed to sell 12,621,359 firm shares. The underwriters' 30-day option for up to 1,893,203 additional shares was exercised in full on May 30, 2024, bringing the total to 14,514,562 shares.

  2. What are the expected proceeds to Insmed?

    The filing states net proceeds of approximately $713.9 million before other estimated offering expenses, based on a price of $49.1825 per share after underwriting discounts and commissions. The pricing press release states gross proceeds of approximately $650 million at a public offering price of $51.50 per share.

  3. What will Insmed use the money for?

    According to the pricing press release, net proceeds will fund continued R&D of brensocatib, pre-commercial and, if approved, commercialization of brensocatib, further commercialization and development of ARIKAYCE, R&D of TPIP and other research product candidates, and general corporate purposes, including business expansion.

  4. When is the offering expected to close, and under what registration?

    The company and underwriters expect the sale and purchase of the firm shares to close on May 31, 2024, subject to customary closing conditions. The offering is made under Form S-3 shelf registration statement No. 333-272088, which became automatically effective on May 19, 2023.

04—Continue

← View all 8-K filings